GATA2 expression in continuous CR, RD, and clinical relapse. Consecutive GATA2 expression at diagnosis and at different time points during treatment in a cohort of 38 pediatric AML patients from whom material was available for MRD analysis. GATA2 expression was determined using real-time quantitative PCR at diagnosis (n = 38), after the first cycle of induction therapy (n = 27), after completion of induction therapy (n = 23), after the first cycle of consolidation therapy (n = 12), after completion of consolidation therapy (n = 25), and at relapse (n = 10). Expression relative to GAPDH is plotted. GATA2 expression in patients with continuous CR1 (A; n = 21), relapse (B; n = 12), and RD (C; n = 2). Patients were subdivided into patients with high GATA2 expression at diagnosis versus normal GATA2 expression at diagnosis. GATA2 expression was considered to be high when the expression was 2 SD above the median GATA2 expression obtained in normal BM (n = 74), which was determined by real-time quantitative PCR. The threshold is depicted as a dashed line.